Adverum Biotech Stock Price, News & Analysis

Adverum Biotechnologies (NASDAQ:ADVM) announced its participation in the upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Laurent Fischer, MD, President and CEO, along with Szilárd Kiss, MD, Distinguished Professor of Ophthalmology and Board Member, will engage in a fireside chat on August 13, 2025, at 9:00 AM EDT.

The presentation will be accessible via live webcast through Adverum's website investor section, with a replay available for at least 30 days after the event.

Adverum Biotechnologies (NASDAQ: ADVM) has granted inducement awards to two new employees under its 2017 Inducement Plan, as approved by the company's Compensation Committee. The awards include non-qualified stock options to purchase 9,740 shares at $2.22 per share and 4,870 restricted stock units (RSUs). The stock options vest over four years with 25% vesting after one year and the remainder monthly over three years, while RSUs vest over three years with one-third vesting annually. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements and are subject to continuous employment requirements.

Adverum Biotechnologies (NASDAQ: ADVM) reported Q1 2025 financial results and pipeline updates for its gene therapy treatment Ixo-vec. The company launched ARTEMIS, the first registrational intravitreal gene therapy trial for wet AMD, enrolling both treatment-experienced and treatment-naïve patients. At ARVO 2025, they presented groundbreaking data showing cell-level mapping of Ixo-vec's effectiveness 3.5 years post-administration. Key financials show a net loss of $47.0 million ($2.25 per share) compared to $27.1 million in Q1 2024. Cash position stands at $83.1 million, expected to fund operations into H2 2025. R&D expenses increased to $28.7 million from $15.4 million year-over-year. The company plans to initiate its second Phase 3 trial, AQUARIUS, in H2 2025 and present two-year LUNA follow-up data in Q4 2025.

Adverum Biotechnologies (NASDAQ: ADVM) has granted inducement awards to seven new employees under its 2017 Inducement Plan. The awards include non-qualified stock options to purchase 32,620 shares of common stock at $3.33 per share and restricted stock units (RSUs) for 16,310 shares. The stock options vest over four years with 25% vesting in the first year and the remainder monthly over three years. The RSUs vest over three years, with one-third vesting annually. These grants were approved as inducement material for new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

Adverum Biotechnologies (ADVM) has reported its Q4 and full year 2024 financial results, highlighting significant progress with its Ixo-vec gene therapy for wet AMD treatment. The company has initiated ARTEMIS, their first pivotal trial, which will evaluate Ixo-vec in approximately 284 patients.

The company's cash position stood at $125.7 million as of December 31, 2024, expected to fund operations into H2 2025. Q4 2024 resulted in a net loss of $40.9 million ($1.96 per share), compared to $24.5 million in Q4 2023. R&D expenses increased to $24.1 million from $15.3 million, while G&A expenses rose to $18.5 million from $11.7 million year-over-year.

Key upcoming milestones include the initiation of the global AQUARIUS Phase 3 trial in H2 2025 and presentation of Phase 2 LUNA two-year follow-up data in Q4 2025.

Adverum Biotechnologies (NASDAQ: ADVM) has announced an inducement grant for a new employee under its 2017 Inducement Plan. The Compensation Committee approved non-qualified stock options to purchase 30,000 shares of common stock at an exercise price of $3.83 per share, matching Adverum's closing price on the grant date.

The stock options will vest over a four-year period, with 25% vesting after the first year and the remaining shares vesting monthly at 1/48th over the subsequent 36 months, contingent on the employee's continued service with Adverum. The grant was approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference. The company will engage in a fireside chat scheduled for Thursday, April 3 at 10:45 a.m. ET.

Interested parties can access the webcast through the Events and Presentations section of Adverum's website in the Investors area. The recording will remain available for a minimum of 30 days after the event.

Adverum Biotechnologies (Nasdaq: ADVM) has initiated ARTEMIS, a pioneering Phase 3 study evaluating Ixo-vec, a one-time gene therapy for wet AMD. The US-based trial will assess a single Ixo-vec injection versus aflibercept in 284 patients, including both treatment-naïve and previously treated individuals.

The study's primary endpoint measures change in best corrected visual acuity at one year, with a non-inferiority margin of -4.5 letters. ARTEMIS is the first of two planned Phase 3 registrational trials, with the second study (AQUARIUS) to be conducted globally.

Key trial design features include:

• Single administration of Ixo-vec (6E10 vg/eye) compared to aflibercept (2mg) every 8 weeks
• Three loading doses of aflibercept prior to Ixo-vec administration
• Eligibility for supplemental aflibercept injections
• Prophylactic steroid eye drops for all patients

Adverum Biotechnologies (ADVM) has granted inducement awards to 5 new employees under its 2017 Inducement Plan. The awards include:

• Non-qualified stock options to purchase 44,380 shares at $4.20 per share
• Restricted stock units (RSUs) for 22,790 shares

The stock options will vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly over 36 months. The RSUs will vest over 3 years, with one-third vesting annually. Both awards are contingent on continued employment with Adverum. These grants were approved by the Compensation Committee as inducement material for new employment in accordance with Nasdaq Listing Rule 5635(c)(4).